Award
NIH Reporter #5R41AI186746-02
A whole-cell inactivated vaccine for improved protection against tuberculosis
Recipient
SOLARIS VACCINES, INC.
Award Amount
$274,002.00
Ceiling
$274,002.00
Awarded
August 14, 2026
Identifier
5R41AI186746-02
NIH grant awarded to SOLARIS VACCINES, INC. for developing a novel TB vaccine using UV-inactivated Mtb to enhance mucosal immunity and protection, supporting progression to clinical trials.
Description
Development of SolaVAX-TB, a whole-cell inactivated Mycobacterium tuberculosis vaccine using riboflavin and UV light, aimed at improving protection against tuberculosis by eliciting mucosal immunity. The project evaluates safety, immunogenicity, and efficacy of the vaccine as a booster and standalone against high-virulence Mtb challenge to support further clinical development.